Intrepid Financial Planning Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$71.2K Hold
30,150
0.03% 123
2025
Q4
$63.6K Hold
30,150
0.02% 120
2025
Q3
$51.6K Hold
30,150
0.02% 126
2025
Q2
$35K Hold
30,150
0.01% 121
2025
Q1
$33.2K Hold
30,150
0.02% 116
2024
Q4
$51.9K Hold
30,150
0.02% 119
2024
Q3
$74.8K Hold
30,150
0.03% 121
2024
Q2
$73K Hold
30,150
0.03% 122
2024
Q1
$122K Hold
30,150
0.05% 120
2023
Q4
$116K Hold
30,150
0.06% 114
2023
Q3
$125K Buy
30,150
+10,000
+50% +$61.8K 0.06% 110
2023
Q2
$96.9K Sell
20,150
-10,000
-33% -$47.9K 0.05% 116
2023
Q1
$122K Buy
30,150
+20,150
+202% +$105K 0.06% 113
2022
Q4
$54K Buy
+10,000
New +$67.2K 0.03% 112

Other funds holding ABOS

Intrepid Financial Planning Group's ABOS Position: Q1 2026 in Review

Intrepid Financial Planning Group held its Acumen Pharmaceuticals (ABOS) position steady in Q1 2026 at 30,150 shares worth $71.2K. The position accounts for 0.03% of the portfolio, ranked #123.

Intrepid Financial Planning Group first reported a position in ABOS in Q4 2022 and has held it in 14 quarters since. The position peaked at $125K in Q3 2023. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Intrepid Financial Planning Group held 30,150 shares of Acumen Pharmaceuticals worth $71.2K as of Q1 2026.
  • Intrepid Financial Planning Group left its Acumen Pharmaceuticals share count unchanged in Q1 2026.
  • Acumen Pharmaceuticals made up 0.03% of Intrepid Financial Planning Group's portfolio in Q1 2026, its #123 holding.
  • Intrepid Financial Planning Group first reported a position in Acumen Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Intrepid Financial Planning Group's Acumen Pharmaceuticals position peaked at $125K in Q3 2023.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Intrepid Financial Planning Group's 13F filing for Q1 2026, filed 13 May 2026.